PHARMA NORD ApS: Financial statements 2024
CVR: 67303016
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
PHARMA NORD ApS (CVR 67303016) has filed annual accounts for 2024. In 2024, the company reported revenue of DKK 486,691,000 and a net result of DKK 32,254,000 compared with DKK 23,337,000 the year before. That is an increase of 8.8% compared with the year before. The profit margin was 6.6%. Equity in the 2024 report amounted to DKK 143,344,000. The solvency ratio was 35.4%. The company had 440 employees in the financial year.
- Revenue
- DKK 486,691,000
- Gross Profit
- DKK 180,348,000
- Profit/Loss
- DKK 32,254,000
- Equity
- DKK 143,344,000
- Total Assets
- DKK 405,332,000
- Employees
- 440
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | 486.7 mio. | 180.3 mio. | 32.3 mio. | 143.3 mio. | 440 |
| 2023 | 447.4 mio. | 147.6 mio. | 23.3 mio. | 160.6 mio. | 416 |
| 2022 | 439.4 mio. | 187.5 mio. | 35.3 mio. | 183 mio. | 425 |
| 2021 | 470.2 mio. | 221 mio. | 58 mio. | 199.3 mio. | 420 |
| 2020 | 417.2 mio. | 197.9 mio. | 51.9 mio. | 170.4 mio. | 394 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
PHARMA NORD ApS has published its annual report for 2023. Revenue came to DKK 447,388,000, and the net result was DKK 23,337,000.
About PHARMA NORD ApS
PHARMA NORD ApS is a Danish company of the type Anpartsselskab based in Vojens, founded in 1981. The company is registered under the industry Fremstilling af andre fødevarer i.a.n.. The company was previously named DANMARKS HELSEKOST DISTRIBUTION ApS. The management consists of Eli Wallin. The board consists of Michael Christiani Havemann (chair) and Eli Wallin. The company is owned by PHARMCO I ApS and PharmCo III ApS. The company has 298 employees (2026). In 2025, the company reported revenue of DKK 518,005,000 and a net result of DKK 26,711,000 compared with DKK 32,254,000 the year before. Equity in the 2025 report amounted to DKK 181,417,000.